Lucid Diagnostics, Inc.(NASDAQ : LUCD)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Medical Specialties
|TMO||Thermo Fisher Scientific, Inc.||-0.81%||538.89||1.0%||$620.13m|
|ISRG||Intuitive Surgical, Inc.||0.42%||201.56||0.8%||$422.82m|
|BSX||Boston Scientific Corp.||0.13%||37.32||1.0%||$329.71m|
|ALGN||Align Technology, Inc.||2.25%||242.00||6.4%||$284.05m|
|BDX||Becton, Dickinson & Co.||0.65%||248.14||1.0%||$274.60m|
|EW||Edwards Lifesciences Corp.||0.54%||95.60||0.4%||$254.65m|
|IDXX||IDEXX Laboratories, Inc.||0.33%||351.89||3.8%||$222.27m|
|BAX||Baxter International, Inc.||0.22%||64.37||1.8%||$197.45m|
|A||Agilent Technologies, Inc.||-0.85%||117.76||1.7%||$196.76m|
|SWAV||Shockwave Medical, Inc.||2.16%||195.30||0.0%||$169.73m|
Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.